Sargramostim for active Crohn's disease

被引:253
作者
Korzenik, JR
Dieckgraefe, BK
Valentine, JF
Hausman, DF
Gilbert, MJ
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Inflammatory Bowel Dis Ctr, Boston, MA USA
[2] Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO 63110 USA
[3] Univ Florida, Div Gastroenterol Hepatol & Nutr, Gainesville, FL USA
[4] Vet Affairs Med Ctr, Gainesville, FL 32608 USA
[5] Berlex Labs Inc, Seattle, WA USA
关键词
D O I
10.1056/NEJMoa041109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Sargramostim, granulocyte-macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the intestinal innate immune system. Preliminary studies suggest sargramostim may have activity in Crohn's disease. To evaluate this novel therapeutic approach, we conducted a randomized, placebo-controlled trial. Methods Using a 2:1 ratio, we randomly assigned 124 patients with moderate-to-severe active Crohn's disease to receive 6 mug of sargramostim per kilogram per day or placebo subcutaneously for 56 days. Antibiotics and aminosalicylates were allowed; immunosuppressants and glucocorticoids were prohibited. The primary end point was a clinical response, defined by a decrease from baseline of at least 70 points in the Crohn's Disease Activity Index (CDAI) at the end of treatment (day 57). Other end points included changes in disease severity and the health-related quality of life and adverse events. Results There was no significant difference in the rate of the primary end point of a clinical response defined by a decrease of at least 70 points in the CDAI score on day 57 between the sargramostim and placebo groups (54 percent vs. 44 percent, P=0.28). However, significantly more patients in the sargramostim group than in the placebo group reached the secondary end points of a clinical response defined by a decrease from baseline of at least 100 points in the CDAI score on day 57 (48 percent vs. 26 percent, P=0.01) and of remission, defined by a CDAI score of 150 points or less on day 57 (40 percent vs. 19 percent, P=0.01). The rates of either type of clinical response and of remission were significantly higher in the sargramostim group than in the placebo group on day 29 of treatment and 30 days after treatment. The sargramostim group also had significant improvements in the quality of life. Mild-to-moderate injection-site reactions and bone pain were more common in the sargramostim group, and three patients in this group had serious adverse events possibly or probably related to treatment. Conclusions This study was negative for the primary end point, but findings for the secondary end points suggest that sargramostim therapy decreased disease severity and improved the quality of life in patients with active Crohn's disease.
引用
收藏
页码:2193 / 2201
页数:9
相关论文
共 29 条
[1]   Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor [J].
Armitage, JO .
BLOOD, 1998, 92 (12) :4491-4508
[2]  
BEST WR, 1979, GASTROENTEROLOGY, V77, P843
[3]   NEUTROPHIL DYSFUNCTION IN GLYCOGEN-STORAGE-DISEASE-IB - ASSOCIATION WITH CROHNS-LIKE COLITIS [J].
COUPER, R ;
KAPELUSHNIK, J ;
GRIFFITHS, AM .
GASTROENTEROLOGY, 1991, 100 (02) :549-554
[4]   Association of glycogen storage disease 1b and Crohn disease: results of a North American survey [J].
Dieckgraefe, BK ;
Korzenik, JR ;
Husain, A ;
Dieruf, L .
EUROPEAN JOURNAL OF PEDIATRICS, 2002, 161 (Suppl 1) :S88-S92
[5]   Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor [J].
Dieckgraefe, BK ;
Korzenik, JR .
LANCET, 2002, 360 (9344) :1478-1480
[6]   Identification of GM-CSF in Paneth cells using single-cell RT-PCR [J].
Fukuzawa, H ;
Sawada, M ;
Kayahara, T ;
Morita-Fujisawa, Y ;
Suzuki, K ;
Seno, H ;
Takaishi, S ;
Chiba, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 312 (04) :897-902
[7]   Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection [J].
Girardin, SE ;
Boneca, IG ;
Viala, J ;
Chamaillard, M ;
Labigne, A ;
Thomas, G ;
Philpott, DJ ;
Sansonetti, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) :8869-8872
[8]   INFLAMMATORY BOWEL-DISEASE AND ADENOMAS IN MICE EXPRESSING A DOMINANT-NEGATIVE N-CADHERIN [J].
HERMISTON, ML ;
GORDON, JI .
SCIENCE, 1995, 270 (5239) :1203-1207
[9]   CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells [J].
Hisamatsu, T ;
Suzuki, M ;
Reinecker, HC ;
Nadeau, WJ ;
McCormick, BA ;
Podolsky, DK .
GASTROENTEROLOGY, 2003, 124 (04) :993-1000
[10]   Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease [J].
Hugot, JP ;
Chamaillard, M ;
Zouali, H ;
Lesage, S ;
Cézard, JP ;
Belaiche, J ;
Almer, S ;
Tysk, C ;
O'Morain, CA ;
Gassull, M ;
Binder, V ;
Finkel, Y ;
Cortot, A ;
Modigliani, R ;
Laurent-Puig, P ;
Gower-Rousseau, C ;
Macry, J ;
Colombel, JF ;
Sahbatou, M ;
Thomas, G .
NATURE, 2001, 411 (6837) :599-603